Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oralin/Oralgen: Phase I data; Phase II

GNBT said that in 15 healthy volunteers,

Read the full 75 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE